IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ImmunityBio Inc (IBRX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The stock has strong growth potential driven by positive regulatory developments, promising trial results, and analyst optimism. While there are some financial challenges, the company's revenue growth and strategic advancements outweigh the risks for a long-term investment.
The technical indicators are moderately bullish. The MACD histogram is positive and contracting, RSI is neutral at 60.489, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point of 8.95, with resistance at 11.433 and support at 6.467.
European Union approval for Anktiva, expanding its footprint to 33 countries.
Completion of a pivotal trial with 85% efficacy for Anktiva plus BCG, with plans to submit a biologics license application by Q4
Founder Patrick Soon-Shiong's strong control and market confidence in the company.
Analysts have raised price targets, with H.C. Wainwright setting a target of $15.
Financial challenges persist, with negative net income (-$61.94M) and declining EPS (-25% YoY).
High implied volatility (IV percentile 98.
suggests potential price swings, which could be risky for some investors.
In Q4 2025, revenue increased by 406.95% YoY to $38.29M, showing strong growth. However, net income remains negative at -$61.94M, despite a 4.7% YoY improvement. EPS dropped by 25% YoY to -0.06, and gross margin slightly declined by 1%.
Analysts are optimistic, with H.C. Wainwright raising the price target to $15 and Jefferies raising it to $9. Both maintain a Buy rating, citing the company's regulatory progress and pipeline expansion opportunities.
